**Transcriptional profiling reveals altered biological characteristics of chorionic stem cells from women with gestational diabetes**

Liyun Chen1,2, Chung-Teng Wang3,Nicholas R. Forsyth1,4, and Pensee Wu 1,5,6

1Guy Hilton Research Centre, School of Pharmacy and Bioengineering, Keele University, Stoke-on-Trent, UK

2Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO, USA

3Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan

4School of Life Science, Guangzhou University, Guangzhou 510006, China

5Academic Unit of Obstetrics and Gynaecology, University Hospital of North Midlands, Stoke-on-Trent, UK

6Keele Cardiovascular Research Group, School of Primary, Community, and Social Care, Keele University, Stoke-on-Trent, UK

Correspondence to: Nicholas R. Forsyth (n.r.forsyth@keele.ac.uk)

Address: Guy Hilton Research Centre, School of Pharmacy and Bioengineering, Keele University, Thornburrow Drive, Stoke-on-Trent, U.K.

Tel: +44 1782 674388

Fax: +44 1782 674467

**Abstract**

**Background**

Gestational diabetes (GDM) is a common complication of pregnancy. The impact of pregnancy complications on placental function suggests that extraembryonic stem cells in the placenta may also be affected during pregnancy. Neonatal-tissue derived stem cells, with the advantages of their differentiation capacity and non-invasive isolation processes, have been proposed as a promising therapeutic avenue for GDM management through potential cell therapy approaches. However, the influence of GDM on autologous stem cells remains unclear. Thus, studies that provide comprehensive understanding of stem cells isolated from women with GDM are essential to guide future clinical applications.

**Methods**

Human chorionic membrane-derived stem cells (CMSCs) were isolated from placentas of healthy and GDM pregnancies. Transcriptional profiling was performed by DNA microarray and differentially regulated genes between GDM- and Healthy- CMSCs were used to analyse molecular functions, differentiation, and pathway enrichment. Altered genes and biological functions were validated via real-time PCR and *in vitro* assays.

**Results**

GDM-CMSCs displayed, vs. Healthy-CMSCs, 162 upregulated genes associated with increased migration ability, epithelial development, and growth factor-associated signal transduction while the 269 downregulated genes were strongly linked to angiogenesis and cellular metabolic processes. Notably, significantly reduced expression of detoxification enzymes belonging to the aldehyde dehydrogenase gene families (ALDH1A1/1A2, ALDH2, ALDH3) accounted for downregulation across several metabolic pathways. ALDH activity and inhibitor assays indicated that reduced gene expression of ALDHs affected ALDH enzymatic functions and resulted in oxidative stress dysregulation in GDM-CMSCs.

**Conclusion**

Our combined transcriptional analysis and *in vitro* functional characterisation have provided novel insights into fundamental biological differences in GDM- and Healthy- CMSCs. Enhanced mobility of GDM-CMSCs may promote MSC migration towards injured sites; however, impaired cellular metabolic activity may negatively affect any perceived benefit.

**Keywords**

Aldehyde dehydrogenase; Chorionic stem cells; Gestational diabetes; Microarray analysis; Migration

**Background**

Mesenchymal stem cells (MSCs) are present in many adult tissues and play a role in tissue regeneration and maintenance. Their regenerative potential provides numerous benefits for disease treatment[1]. In terms of differentiation potential toward multiple lineages and their inherent immunomodulatory capacity MSC from different tissues may share an element of a common transcriptional signature[2]. However, transcriptional profiles have also been shown to be unique for MSCs derived from different tissues[3-5]. Stem cell therapies remain hampered by our incomplete knowledge of these fundamental differences[6]. Unlike embryonic stem cells, the MSC niche in specific adult tissues may affect and determine the gene expression in those specific tissue-derived MSCs[7]. It is highly likely that many genes critical to regenerative functions of MSCs or altered gene signatures associated with different MSC sources are not understood. An improved knowledge of MSC gene profiles would facilitate effective strategies for the use of MSCs in regeneration medicine.

Placenta has a pivotal role in embryogenesis, contains plentiful undifferentiated stem cells and as part of the extra-embryonic tissue, and stem cells can be isolated from the placenta without additional invasive procedures or additional ethical concerns[8]. During embryogenesis, the extraembryonic mesoderm surrounding the amniotic cavity gives rise to the placental membrane, composed of amniotic and chorionic mesoderm[9]. Chorionic MSCs (CMSCs) are derived from the chorion and share common MSCs characteristics and multipotency[10, 11]. As CMSCs emerge during pregnancy, their characteristics are highly likely to be affected by pregnancy complications. Gestational diabetes mellitus (GDM) is a common pregnancy complication defined by the new onset of glucose intolerance during pregnancy[12]. The hyperglycaemic environment leads to long-term adverse effects on the offspring and the mother, including increased risk of GDM in subsequent pregnancies and type 2 diabetes in later life[13]. Previous studies have shown that maternal GDM had an adverse effect on proliferation and viability of umbilical cord derived MSCs[14], as well as low yield rate of perivascular stem cells from umbilical cords[15]. Chorionic villi derived mesenchymal stromal cells exhibited decreased clonogenicity and angiogenic potential in GDM compared with healthy pregnancies[16]. However, the underlying molecular events behind those observed differences remain unclear.

A microarray study on umbilical vein endothelial cells derived from GDM pregnancies indicated altered gene expression in insulin sensing and extracellular matrix reorganisation[17]. Gene profiles of umbilical cord tissue from diabetic pregnancies showed alterations in genes associated with vascular development and function [18]. It is noticeable that very few studies have investigated the MSC transcriptional signature altered by pregnancy complications. Not only is gene profiling research on the regenerative ability of MSCs from GDM pregnancies limited, but microarray profiling of CMSCs is yet to be described and made publically available.

With increasing interest in the utilisation of placental MSCs and their banking for clinical purposes, understanding the characteristics and regenerative potential of placental MSCs has become an important subject. Thus, we sought to explore gene expression profiles between CMSCs isolated from healthy and GDM placenta and establish biological differences or similarities. Our findings demonstrate the influence of GDM on CMSCs transcriptional profiles with corresponding changes in functionality through *in vitro* assays. The observed enhanced migration and epithelial development potential in GDM-CMSCs may have clinical benefits for wound healing. On the other hand, the decreased expression and activity of ALDH detoxification enzymes in GDM-CMSCs leads to downregulation of several degradation pathways and an impaired ability to respond to oxidative stress. The comprehensive understanding of GDM-CMSCs reveals the benefits and disadvantages of utilising CMSCs from GDM pregnancies for future regenerative medicine.

**Materials and Methods**

**Human samples**

Placenta samples were obtained with informed written consent and in accordance with procedures approved by Research Ethics Committee and Health Research Authority (Reference 15/WM/0342). Full-term placentas from 10 heathy and 11 GDM pregnancies were collected from Royal Stoke University Hospital, UK.

**Cell isolation and culture**

All placentas were collected immediately after Caesarean section and cell isolation was performed within 1 hour. CMSCs were isolated from chorionic membrane and characterised by immunophenotyping with high levels of expression of typical MSC markers; CD73, CD90, CD105, and low levels of CD14, CD19, CD34, CD45 and HLA-DR. CMSC isolation, as previously described[19], was performed by removing amniotic membrane and decidual tissue from chorionic membrane, digesting with 0.05% trypsin/EDTA solution followed by digestion media containing 1 mg/ml collagenase type IV and 25 µg/ml DNase I (Thermo Scientific) in serum free Dulbecco’s Modified Eagle Medium (DMEM, Lonza). Cell were cultured in DMEM consisting of 10% fetal bovine, serum 1% L-glutamine, and 1% non-essential amino acids (NEAA, Lonza). The CMSCs samples used in DNA microarray were from 3 heathy and 3 GDM pregnancy at passage 3. Other samples were used for validation of microarray data by analysis gene expression through qPCR and functional assays.

**DNA microarray**

0.2 μg of total RNA was amplified and labelled with Cy3 (CyDye, Agilent Technologies) for in vitro transcription process. Labelled cRNA was pooled and hybridized to Agilent SurePrint Microarray (Agilent Technologies) according to the manufacturer’s protocol. Arrays were scanned with an Agilent microarray scanner and images analyzed by Feature extraction10.7.3.1 software (Agilent Technologies).

**Microarray analysis using bioinformatics software**

Venn diagram and hierarchical clustering heat maps were created by AltAnalyze software (Gladstone Institution, UCSF) and used to identify commonly upregulated or down-regulated genes and illustrate the differentially expressed gene lists of interest.

Ingenuity Pathway Analysis (IPA, Qiagen; www.qiagen.com/ingenuity) was used to analyse genes with fold changes >1.5 in GDM samples vs. healthy samples. Overrepresented and underrepresented biological functions and canonical pathways was identified based on the selected genes using Ingenuity Knowledge Database (Qiagen). The p-value, calculated with the Fisher's exact test, indicates the likelihood that the association between a set of genes in the experimental dataset and a biological function or pathway is the result of random chance. The p value < 0.05 indicates a statistically significant. Z-score based on the match of target genes and biological pathway/function; expression changes of these target genes and their agreement with literature finding predicted the up/down regulation patterns.

Pathway network visualisation was created by Cytoscape v.3.6.1. Enriched gene sets identified by IPA pathway analysis were selected and used as input nodes. The interaction network was generated according to literature findings and public database. The network was manually curated and distributed with circles for easier visualisation.

**RNA extraction and real-time PCR**

Total RNA were isolated at passage 3, using TRIzol Reagent (Invitrogen) according to the manufacturer’s instruction. Reverse transcription was performed with High-Capacity cDNA Reverse Transcription Kit (Thermo Scientific). Gene expression analysis was evaluated by real-time PCR using QuantiFast SYBR Green PCR Kit (Qiagen). Primer sequences are shown in Table 1. The relative expression levels of mRNA were normalised to *GAPDH* and fold change was calculated using the 2^-(ΔΔCt) method.

**Transwell migration assay**

Cells were placed onto the upper chamber of a Transwell filter with 8 μm pores (Corning) and bottom well contained regular growth media culturing in 37℃ incubator. After 8 and 24 hours, migrated cells were fixed with methanol and stained with crystal violet. Migration was quantified by cell counts in five separate fields per sample and expressed as mean numbers. Data represent 6 independent experiments in each group, performed in triplicate.

**Wound healing assay**

5x105 cells were seeded into each well of a 6-well plate and cultured for 2 days. Wounds were created by scratching with a 200-μl pipette tip and media was changed to remove suspension cells. After incubating for 12 h, cells were visualized under a light microscope. Relative cell migration was calculated by measuring final wound area compared to initial area. Three non-overlapping fields were picked and examined per well. Data represent 6 independent experiments in each group.

**ALDH activity analysis**

ALDH function was measured by aldehyde dehydrogenase activity colorimetric assay kit (Sigma). Acetaldehyde is oxidized by ALDH generating NADH which reacts with a probe and the activity of ALDH measured by absorbance reading at 450 nm. Cells were lysed by ALDH buffer and manufacturer’s protocol followed. Absorbance was measured every 5 minutes over a 30-minute period. The activity of ALDH was calculated according to manufacturer’s suggestion. All samples were performed in triplicate.

**Detection of intracellular ROS**

ROS was detected by 2’,7’ - dichlorofluorescin diacetate (DCFDA, also known as H2DCFDA) cellular reactive oxygen species detection kit (Abcam). Cells were seeded at 10,000 cells/well in a 96-well plate. After attachment, cells were incubated with 25 μM DCFDA for 45 min at 37°C and then treated with 5mM or 25mM glucose. For florescent images, ROS detection was observed by confocal microscope. Images were taken from randomly chosen fields in each experiment. The intensity of florescence was measured by microplate reader and signal was read at excitation/emission: 485/535 nm. A blank well containing no cells (media only) was used as background signal. All samples were performed in triplicate.

**Statistics**

All statistics were calculated by GraphPad Prism 6 software. Student’s t-test was used to compare paired or unpaired data. Value are presented as mean ± SEM and *P* < 0.05 is determined as significant. \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001.

**Results**

**Identification of differentially expressed genes and biological function analysis**

Gene expression profiles of CMSCs derived from 3 healthy (H-CMSCs) and 3 GDM women (GDM-CMSCs) were determined by DNA microarray analysis. Validation of microarray results was performed with 10 H-CMSCs and 11 GDM-CMSCs samples. Applying a cut-off of *P* < 0.05 and 1.5-fold change between H-CMSCs and GDM-CMSCs we identified a total of 431 differentially expressed genes (DEGs), including 162 upregulated and 269 downregulated genes in all 3 GDM samples (Fig. 1a). The 3 GDM women were treated for their GDM with either metformin (GDM6), insulin (GDM7), or both (GDM8). The sample from the women received both metformin and insulin treatment exhibited the highest number of total DEGs.

Biological function analysis using DEGs identified in all 3 GDM-CMSCs samples was performed with Ingenuity Pathway Analysis (IPA) focussed on two categories: “molecular and cellular functions” and “physiological system development and functions”. Applying a cut-off of average -log(p-value)>30 using Fisher's exact test, the most represented “molecular and cellular functions” in GDM-CMSCs were related to cell death and survival, cellular growth and proliferation, and cellular movement (Fig. 1b). To further identify the altered downstream cellular process of the most represented biological functions, the activation z-score computed by IPA were used to infer the activation/inhibition state and gene enrichment. A positive z-score indicates increased functional activity in GDM-CMSCs relative to H-CMSCs while a negative z-score indicates a reduction in activity. Positively associated cellular processes in GDM-CMSCs included cell survival, viability, cellular migration and movement, assembly and organization of cytoskeleton, and skin formation, which are critical functions in wound repair and tissue remodelling (Fig. 1c). DEGs in GDM-CMSCs associated with the positively regulated cellular processes were displayed by gene clustering heat maps, indicating the upregulated expression levels and increased wound healing and remodelling potential (Fig. 1d). Noticeably, organismal death was the most downregulated cellular process in GDM-CMSCs while other negatively associated functions including stimulation of cells, homing, and colony formation showed less significant z-score values (Fig. 1c).

**Differentially expressed genes in GDM-CMSCs are significantly involved in cardiovascular system development**

In terms of the tissue regenerative potential of GDM-CMSCs, the most represented biological function in the “physiological system development” category was cardiovascular system development and function, which had an average -log(p-value)>30 (Fig. 1e). Further in-depth analysis of the downstream functional activation performed in relation to cardiovascular system development showed that cardiogenesis was the most significantly over-represented downstream cellular process with the highest positive z-score, along with the positive association with development of cardiovascular tissue (Fig. 1f). The heat map illustrated a set of genes involved in cardiogenesis that were highly expressed in GDM-CMSCs compared to H-CMSCs, suggesting the greater potential of GDM-CMSCs in cardiac regeneration (Fig. 1g). In contrast, the cellular processes of vasculogenesis and angiogenesis in cardiovascular development had decreased activation with negative z-scores (Fig. 1f). The heat map showed the downregulation of vasculogenesis and vasculature development-associated genes in GDM-CMSCs compared with H-CMSCs (Fig. 1g). Moreover, other enriched downstream cellular processes in the “physiological system development” category included respiratory system development, formation of lung and kidney with positive z-score while development of exocrine gland and connective tissue had negative z-scores in GDM-CMSCs (Additional file 1: Figure S1).

**Validation of increased migration ability, wound healing potential, and cardiac development in GDM-CMSCs**

To evaluate functional differences between H-CMSCs and GDM-CMSCs, elevated expression of genes involved in migration, survival, and cellular assembly ability in GDM-CMSCs were validated though real-time PCR and migration assays. DEGs associated with cell migration (*CD24, AQP1*), cellular assembly (*FLNB, CELSR1*) and skin formation and healing process (*EDN1, HBEGF, TGFB2, CTGF*) were significantly upregulated in GDM-CMSCs compared to H-CMSCs (Fig. 2a and Additional file 2: Figure S2a). Transwell migration was performed to examine cell motility, where H-/GDM- CMSCs were placed into the upper compartment of a Transwell filter and allowed to migrate through the filter for 8 and 24 hours. After either 8 or 24 hours of incubation, enhanced migration ability was observed in GDM-CMSCs with a greater numbers of cells having migrated across the membrane (Fig. 2b-c). In wound healing assays, higher numbers of GDM-CMSCs migrated into the wound field at every observed time point (6, 12, 24 hours) than H-CMSCs. The closure percentages were significantly increased, with approximately 30 % in GDM-CMSCs and 20 % in H-CMSCs after 12 hours (Fig. 2d and Additional file 3: Figure S3). Collectively, both the Transwell migration and wound healing assay validated the enhanced migration ability in GDM-CMSCs.

Cardiovascular development was identified as the most enriched biological function in GDM-CMSCs with altered gene expression in cardiogenesis and vasculogenesis. The expression of genes associated with cardiogenesis (*NKX2.5, NOG, PDGFA, NPPB, MET*) showed significant increases in GDM-CMSCs vs. H-CMSCs (Fig. 2e and Additional file 2: Figure S2b). The opposite trend was found in vasculogenesis-associated genes, which showed a significantly reduced expression of *RASIP1, CXCL12, RSPO3,* and *HMOX1* in GDM-CMSCs (Fig. 2f and Additional file 2: figure S2b). Taken together, CMSCs derived from GDM placenta may therefore have better potential application in wound repair and cardiogenesis than in vasculogenesis when compared to H-CMSCs.

**Pathways mediating cardiac development and cell movement are both upregulated in GDM-CMSCs**

Gene regulatory networks were examined incorporating DEGs for positively regulated (Fig. 3a) and negatively regulated pathways (Fig. 3b). STAT3 pathway, with roles in development, cellular homeostasis, cell growth, proliferation, and differentiation[20] was the most significantly upregulated signalling pathway in GDM-CMSCs with the highest ratio and -log(p-value). The activation of pathways such as BMP signalling, Wnt/β-catenin signalling, and FGF signalling which were upregulated in GDM-CMSCs may transduce through STAT3 signalling and contribute to the regulation of various development processes. Multiple upregulated genes in GDM-CMSCs were involved in BMP, Wnt/β-catenin, and FGF signalling (Fig. 3C). Additionally, BMP, Wnt/β-catenin, and FGF signalling play an important role in heart development. As the cardiac-associated genes, *NKX2.5* and *NOG* are regulated downstream to BMP, Wnt/β-catenin, and FGF pathways, the previously observed upregulation of *NKX2.5* and *NOG* in GDM-CMSCs may contribute to enhanced cardiogenesis potential via the modulation of BMP, Wnt/β-catenin, and FGF pathways. Other regulatory factors, such as *WNT3/11, LEF1, FZD* in the Wnt/β-catenin signalling pathway, and *FGF1, MAPK, MET* in the FGF signalling pathway also displayed higher expression in GDM-CMSCs than H-CMSCs (Fig. 3c).

Moreover, the increased activity of Rho family GTPase signalling in GDM-CMSCs, including Rac, RhoA, Cdc42 signalling which associate with regulation of cell migration, invasion, and cytoskeleton organization[21]. The clustering map showed increased expression of genes involved in Rho family signalling in GDM-CMSCs, suggesting that enhanced cell movement capacity in GDM-CMSCs may be associated with activation through Rho family signalling (Fig. 3d). Nuclear receptor signalling via LPS/IL-1 mediated inhibition of RXR function pathway also showed increased activity in GDM-CMSCs.

**Significantly reduced expression in ALDH family genes results in negative association with metabolic pathways in GDM-CMSCs**

Among the downregulated metabolic pathways, most were associated with degradation processes, including ethanol degradation, oxidative ethanol degradation, fatty acid α–oxidation as well as the degradation of neurotransmitters (histamine, dopamine, noradrenaline, serotonin) and other molecules (putrescine, tryptophan) (Fig. 3b). Given the dysfunctional metabolic regulation in women with GDM, these pathways are of particular interest for investigating GDM-CMSCs behaviours. Figure 3e illustrates the genes associated with these enriched downregulated pathways and showed that the decreased activities of degradation pathways were connected to the significant reduction in aldehyde dehydrogenase family gene expression, *ALDH1, ALDH2, ALDH3* (Fig. 3e). Aldehydes can be formed during the metabolism of amino acids, carbohydrates, lipids, vitamins as well as cytotoxic drugs and environmental chemicals[22]. ALDH genes encode the key enzymes that regulate cellular detoxification through oxidation of endogenous and exogenous aldehydes, and play an important role in many degradation processes[23]. Notably, *ALDH1A1* is one of the most downregulated genes in GDM-CMSCs (Table 2). Other genes including *ALDH1A2, ALDH2, ALDH3B1* were also significant reduced in GDM-CMSCs microarray data and comprised the core molecules of the downregulated pathways network. The deficiency of ALDH family genes may lead to insufficient detoxification resulting in aldehyde accumulation and reactive oxygen species (ROS) imbalance. Additionally, a critical pathway for ROS regulation, the Nrf2-mediated oxidative stress response pathway, showed downregulation in GDM-CMSCs, owing to the low expression of important regulators, protein kinase (*PRKC*) and antioxidant enzyme genes (*HMOX1, SOD2, AOX1*) (Fig. 3f).

Other downregulated pathways, such as “IL-6 signalling” and “HGF signalling” regulate multiple molecules involved in angiogenesis (Fig. 3b). For instance, *CEBPB, FOS, ELK1,* and *CXCL8* in angiogenesis pathways, displayed low expression in GDM-CMSCs. Moreover, the downregulation of “PI3K/AKT signalling” may affect the potent angiogenic factors, IL-6, IL-8, HGF and VEGF signalling transduction through mediation of the PI3K/AKT pathway to promote angiogenesis[24-26]. Biological function analysis identified downregulated genes in angiogenesis and vasculogenesis as downstream components of IL-6, IL-8, HGF pathways suggesting a regulatory network of reduced angiogenic potential in GDM-CMSCs.

**Reduced ALDH activity in GDM-CMSCs is associated with reactive oxygen species dysregulation**

Given that the decreased expression of ALDH family genes affected several metabolic pathways and the negative activation of Nrf2-mediated oxidative stress regulation, GDM-CMSCs are likely to have imbalanced cellular ROS regulation as reflected in increased oxidative stress which are found in diabetic tissues[27]. The expression of *ALDH1A1, ALDH2, ALDH3B1* in GDM-CMSCs and H-CMSCs was validated with real-time PCR, and demonstrated significantly reduced expression levels in GDM-CMSCs (Fig. 4a-c). We further evaluated ALDH enzymatic function by ALDH colorimetric activity assay using acetaldehyde as a substrate. In the initial 5 minutes, there was no statistical difference in ALDH activity between two groups but significantly lower levels of ALDH activity in GDM-CMSCs was observed at 10, 15, 20, and 25 minutes vs. H-CMSCs. The ALDH activity gradually declined after 25 minutes in both H-CMSCs and GDM-CMSCs. Of note, the highest level of ALDH activity was seen at 15-min post-stimulation, in H-CMSCs (Fig. 4d).

With impaired ALDH activity, accumulation of highly reactive and toxic aldehyde tends to induce ROS formation and increase oxidative stress[28]. Antioxidant defence reduces harmful effects of ROS; however, a significant reduction of antioxidative enzymes, including *NQO1* and *SOD2* in GDM-CMSCs (Fig. 4e), suggested a deficiency in their antioxidant systems. To examine ROS production, H-CMSCs and GDM-CMSCs were stimulated with glucose to induce metabolic activity. Following the stimulation, ROS was produced in both H-CMSCs and GDM-CMSCs while GDM-CMSCs were observed to have higher levels of cellular ROS than H-CMSCs after 2-hour glucose treatment (Fig. 4f). Measuring ROS production over a period of time, the ROS levels increased, at comparable levels, for the first 45 minutes in both H-CMSCs and GDM-CMSCs following stimulating with glucose. Between 45 to 90 minutes, ROS levels showed significantly higher rates of increase in GDM-CMSCs than H-CMSCs. Notably, H-CMSCs did not produce increased amounts of ROS after 90 minutes and showed slightly reduced ROS generation whereas ROS levels in GDM-CMSCs continued to increase and remained elevated (Fig. 4g).

To further elucidate the influence of ALDH activity on ROS regulation, the enzymatic function of ALDHs was supressed by N, N-diethylaminobenzaldehyde (DEAB), a commonly used selective inhibitor of ALDHs. In the present of ALDH inhibitor, the ALDH activity was significantly suppressed in both H-CMSCs and GDM-CMSCs (Fig. 4h). Moreover, when the ALDH function was suppressed, the ROS production was significantly increased during glucose-induced metabolic process (Fig. 4i). DEAB pre-treated H-/GDM- CMSCs produced higher levels of ROS than un-treated H-/GDM- CMSCs. The finding confirmed the strong association between the ALDH function and cellular ROS regulation.

Low levels of ROS are detectable in many metabolic processes; however, when ROS production is in excess of the cellular antioxidant capacity, it contributes to cellular damage. We found that downregulation of Nrf2-mediated oxidative stress regulation pathway and the impaired function of detoxifying enzymes ALDHs, resulted in an insufficient capacity to respond to increased oxidative stress in GDM-CMSCs.

**Discussion**

DNA microarray data provides an understanding of gene profiles and biological functions altered in GDM-CMSCs offering a valuable resource to regenerative medicine development. To conclude from our findings, the uterine environment during pregnancy could impact on the biology of stem cells derived from perinatal tissues. GDM-CMSCs, compared to H-CMSCs, displayed an enhanced migration ability and a transcriptional profile indicating potential in epithelial development and skin formation and a putative role in wound repair. In contrast, ALDH detoxification enzymes were significantly reduced in GDM-CSMCs leading to downregulation of several degradation pathways. Decreased ALDH activity in GDM-CMSCs was also associated with an impaired ability to respond to oxidative stress. Taken together these novel findings derived from microarray and associated functional assays can be useful for exploring suitable clinical uses of CMSCs from GDM and healthy pregnancies.

GDM-CMSCs had a number of upregulated genes involved in cell motility, cytoskeleton organization, survival, epithelial development and skin formation. The ability of transplanted cells to mobilize and migrate to injury sites would enable a direct role in tissue repair and regeneration [29]. A recent study suggested that high glucose treatment increased human umbilical cord-derived MSCs motility and promoted the migration of transplanted MSCs into mouse model wound site [30]. Human umbilical endothelial cells isolated from GDM pregnancies have also shown an increased migration ability potentially reflecting a proangiogenic GDM state [31]. In contrast, reduced wound closure capacity of perivascular stem cells from GDM women[15] and impaired migration of GDM umbilical cord-derived endothelial cells have also been reported[32]. Cell-specific impacts of GDM on motility cannot be ruled out at this time. Here we have demonstrated that GDM-CMSCs display upregulated expression of *AQP1, FLNB, CELSR1,* and *CD24*, which have important roles in cell movement and cytoskeletal remodelling, and that the GDM-MSCs have enhanced motility.

Dehydrated placental membrane has been used as skin substitute for burned and ulcerated surfaces for many years[33, 34] while the presence of MSCs in cryopreserved placental membranes is further described as improving wound-healing therapies[35, 36]. We identified upregulation of epithelial development associated genes and regulators (*EDN1, KRT14, HBEGF, TGFB2*) in GDM-CMSCs, which may be beneficial for the clinical use as skin substitutes. The downregulation of vasculogenic factors (*RASIP1, CXCL12, RSPO3*) and the decreased activation of angiogenesis inducing pathways (IL-6, IL-8) were observed in GDM-CMSCs. It is noteworthy that hypervascularisation is frequently observed in GDM placentas due to hyperinsulinemia-mediated accelerated fetal metabolism and oxygen uptake, which leads to an imbalance in oxygen supply and demand resulting in hypoxia-induced angiogenesis[37]. Although it would be sensible to assume the involvement of GDM-CMSCs in hypervascularisation, CMSCs derived from GDM placenta did not show an increase in vasculogenesis-associated gene expression or angiogenesis pathway activity, suggesting that CMSCs may not contribute to placental hypervascularisation in GDM. On the contrary, immunohistochemistry staining of increased VEGF protein in cytotrophoblast and syncytiotrophoblast cells of GDM chronic villi[38, 39], flow cytometry identifying elevated levels of VEGF receptors on endothelial progenitor cells from GDM women[40], and increased cytokines production from Hofbauer and placental cells[41], were all associated with enhanced angiogenesis and vasculogenesis in GDM. Various cell types in GDM placenta contribute to hypervascularisation while reduced angiogenic ability in GDM-CMSCs might represent a compensatory response to counteract dysregulated angiogenesis and vascularisation or be implicated in vascular function defects of GDM placenta. In line with a recent study, a decreased *in vitro* tube formation ability accompanied with bFGF and VEGF downregulation was observed in GDM chorionic villi-derived MSCs[16]. Despite the high degree of angiogenesis under the hyperglycaemic environment, MSCs from GDM placenta displayed a weak angiogenic potential. This finding also pointed out the differential effects of GDM on different placental cell types during pregnancy.

Pathways associated with several degradation processes were altered in GDM-CMSCs largely due to the significant reduction of ALDHs expression. As a critical detoxification enzyme, ALDHs are highly expressed in multiple embryonic tissues, stem cells, and progenitor cells[42, 43], and protect cells against oxidative damage through detoxifying exogenous and endogenous aldehyde[28]. ALDH activity has also been used as an indicator for purification of a proangiogenic BM-MSC subset with enhanced secretory functions for vascular regeneration[44]. Significantly reduced ALDH family genes in GDM-CMSCs emphasised the adverse impacts of the pregnancy complication on cellular detoxification. GDM-CMSCs showed significantly lower ALDH enzymatic activity than H-CMSCs, which provided insufficient capacity to manage increased oxidative stress caused by hyperglycaemia. Upon stimulation, ROS production were elevated to a greater extent in GDM-CMSCs than H-CMSCs with no sign of reduction, indicating the impaired cellular ROS regulation in GDM-CMSCs. The vicious circle of increased oxidative stress and decreased antioxidant defence progresses with gestation in GDM pathology[45, 46]. A recent study showed that treating decidual MSCs derived from preeclampsia women with an *ALDH1A1* activator restored *ALDH1A1* activity and improved H2O2-induced oxidative stress resistance in preeclampsia-derived MSCs[47]. The physiologically harmful environment of oxidative stress in GDM may be improved by antioxidant intake[48, 49]; however, restoring ALDH function itself would be a viable therapeutic target of GDM.

Developing therapeutic strategies using autologous MSCs requires a thorough understanding of their biological characteristics *in vitro* and *in vivo*. Although GDM animal models present multiple challenges due to their temporary disease condition and complex inducing factors, several studies have investigated biological properties of MSCs under type I and II diabetes mouse models. For instance, bone marrow MSCs derived from non-obese diabetic mice were found to produce high levels of proinflammatory cytokines, including IL-1α/β and MCP-1[50], streptozotocin-induced diabetic mice showed a reduced number of MSCs and increased apoptosis tendency[51], and one study reported altered tri-lineage differentiation ability in bone marrow and adipose-derived MSCs from high-fat diet-induced obese mice[52]. Various effects of diabetes on MSCs were reported over the years but lack of comprehensive understanding impedes the development of autologous cell therapy. Moreover, relatively little is known about placenta-derived MSCs from GDM pregnancy. Our study provides thorough analysis of genetic profiles of CMSCs from GDM and healthy women, and ultimately *in vitro* functionality will require *in vivo* evaluation and large participation numbers to further elucidate therapeutic potential.

**Conclusion**

In summary, the progression of regenerative medicine and advanced cell banking technology provides an option for the use of perinatal tissue-derived autologous MSCs for personalised medicine. The effect of GDM on CMSCs gene expression was evidenced by DNA microarray analysis coupled to functional assay identification of associated impaired and enhanced functions in GDM-MSCs. These data will assist in the identification and development of suitable applications of GDM-CMSCs and eventually transform the knowledge into clinical practice.

**Declarations**

**Ethics approval and consent to participate**

Studies involving human placenta tissues were collected from Royal Stoke University Hospital, UK, and approved by the Solihull Research Ethics Committee, West Midlands (Reference 15/WM/0342). All women provided written informed consent.

**Availability of data and materials**

All data generated and analysed during this study are available from the corresponding author.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This work was funded by an ISTM/ACORN research grant from Keele University.

**Authors’ contributions**

All authors contributed to experimental design. LC wrote the manuscript. LC and CTW acquired, analysed and interpreted the data. NRF and PW supervised the study, interpreted the data, and revised the manuscript. All authors approved the final version of the manuscript.

**Consent for publication**

Not applicable.

**Acknowledgements**

Not applicable.

**Abbreviations**

ALDH: Aldehyde dehydrogenase

BMP: Bone morphogenetic proteins

CD: Cluster of differentiation

CMSC: Chorionic membrane-derived stem cell

DCFDA: 2’,7’ - dichlorofluorescin diacetate

DEG: Differentially expressed gene

FGF: Fibroblast growth factor

GDM: Gestational diabetes mellitus

IL: Interleukin

IPA: Ingenuity pathway analysis

MSC: Mesenchymal stem cell

PCR: Polymerase chain reaction
ROS: Reactive oxygen species

STAT: Signal transducer and activator of transcription

**References**

[1] F. Gao, S.M. Chiu, D.A. Motan, Z. Zhang, L. Chen, H.L. Ji, H.F. Tse, Q.L. Fu, Q. Lian, Mesenchymal stem cells and immunomodulation: current status and future prospects, Cell Death Dis, 7 (2016) e2062.

[2] A.C. Piscaglia, T. Shupe, A. Gasbarrini, B.E. Petersen, Microarray RNA/DNA in different stem cell lines, Curr Pharm Biotechno, 8 (2007) 167-175.

[3] W. Wagner, F. Wein, A. Seckinger, M. Frankhauser, U. Wirkner, U. Krause, J. Blake, C. Schwager, V. Eckstein, W. Ansorge, A.D. Ho, Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood, Exp Hematol, 33 (2005) 1402-1416.

[4] M. Ramalho-Santos, S. Yoon, Y. Matsuzaki, R.C. Mulligan, D.A. Melton, "Stemness": transcriptional profiling of embryonic and adult stem cells, Science, 298 (2002) 597-600.

[5] R. Donders, J.F.J. Bogie, S. Ravanidis, P. Gervois, M. Vanheusden, R. Maree, M. Schrynemackers, H.J.M. Smeets, J. Pinxteren, K. Gijbels, S. Walbers, R.W. Mays, R. Deans, L. Van Den Bosch, P. Stinissen, I. Lambrichts, W. Gyselaers, N. Hellings, Human Wharton's Jelly-Derived Stem Cells Display a Distinct Immunomodulatory and Proregenerative Transcriptional Signature Compared to Bone Marrow-Derived Stem Cells, Stem Cells Dev, 27 (2018) 65-84.

[6] C. Perez-Iratxeta, G. Palidwor, C.J. Porter, N.A. Sanche, M.R. Huska, B.P. Suomela, E.M. Muro, P.M. Krzyzanowski, E. Hughes, P.A. Campbell, M.A. Rudnicki, M.A. Andrade, Study of stem cell function using microarray experiments, Febs Lett, 579 (2005) 1795-1801.

[7] Y. Kfoury, D.T. Scadden, Mesenchymal cell contributions to the stem cell niche, Cell Stem Cell, 16 (2015) 239-253.

[8] D.M. Delo, P. De Coppi, G. Bartsch, Jr., A. Atala, Amniotic fluid and placental stem cells, Methods Enzymol, 419 (2006) 426-438.

[9] S. Ilancheran, Y. Moodley, U. Manuelpillai, Human fetal membranes: a source of stem cells for tissue regeneration and repair?, Placenta, 30 (2009) 2-10.

[10] L.Y. Chen, M.M. Merkhan, N.R. Forsyth, P. Wu, Chorionic and amniotic membrane-derived stem cells have distinct, and gestational diabetes mellitus independent, proliferative, differentiation, and immunomodulatory capacities, Stem Cell Res, 40 (2019).

[11] J.C. Cross, Formation of the placenta and extraembryonic membranes, Ann N Y Acad Sci, 857 (1998) 23-32.

[12] A. American Diabetes, Diagnosis and classification of diabetes mellitus, Diabetes Care, 36 Suppl 1 (2013) S67-74.

[13] L. Bellamy, J.P. Casas, A.D. Hingorani, D. Williams, Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis, Lancet, 373 (2009) 1773-1779.

[14] N. Wajid, R. Naseem, S.S. Anwar, S.J. Awan, M. Ali, S. Javed, F. Ali, The effect of gestational diabetes on proliferation capacity and viability of human umbilical cord-derived stromal cells, Cell Tissue Bank, 16 (2015) 389-397.

[15] B. An, E. Kim, H. Song, K.S. Ha, E.T. Han, W.S. Park, T.G. Ahn, S.R. Yang, S. Na, S.H. Hong, Gestational Diabetes Affects the Growth and Functions of Perivascular Stem Cells, Mol Cells, 40 (2017) 434-439.

[16] S.A. Mathew, R. Bhonde, Mesenchymal stromal cells isolated from gestationally diabetic human placenta exhibit insulin resistance, decreased clonogenicity and angiogenesis, Placenta, 59 (2017) 1-8.

[17] R. Ambra, S. Manca, M.C. Palumbo, G. Leoni, L. Natarelli, A. De Marco, A. Consoli, A. Pandolfi, F. Virgili, Transcriptome analysis of human primary endothelial cells (HUVEC) from umbilical cords of gestational diabetic mothers reveals candidate sites for an epigenetic modulation of specific gene expression, Genomics, 103 (2014) 337-348.

[18] A. Koskinen, L. Lehtoranta, A. Laiho, J. Laine, P. Kaapa, H. Soukka, Maternal diabetes induces changes in the umbilical cord gene expression, Placenta, 36 (2015) 767-774.

[19] L. Chen, N.R. Forsyth, P. Wu, Chorionic and amniotic placental membrane-derived stem cells, from gestational diabetic women, have distinct insulin secreting cell differentiation capacities, J Tissue Eng Regen Med, (2019).

[20] D.E. Levy, J.E. Darnell, Jr., Stats: transcriptional control and biological impact, Nat Rev Mol Cell Biol, 3 (2002) 651-662.

[21] A.A. Schmitz, E.E. Govek, B. Bottner, L. Van Aelst, Rho GTPases: signaling, migration, and invasion, Exp Cell Res, 261 (2000) 1-12.

[22] V. Vasiliou, D.W. Nebert, Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family, Hum Genomics, 2 (2005) 138-143.

[23] B. Jackson, C. Brocker, D.C. Thompson, W. Black, K. Vasiliou, D.W. Nebert, V. Vasiliou, Update on the aldehyde dehydrogenase gene (ALDH) superfamily, Hum Genomics, 5 (2011) 283-303.

[24] Y. Hou, C.H. Ryu, J.A. Jun, S.M. Kim, C.H. Jeong, S.S. Jeun, IL-8 enhances the angiogenic potential of human bone marrow mesenchymal stem cells by increasing vascular endothelial growth factor, Cell Biol Int, 38 (2014) 1050-1059.

[25] S.H. Jee, C.Y. Chu, H.C. Chiu, Y.L. Huang, W.L. Tsai, Y.H. Liao, M.L. Kuo, Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways, J Invest Dermatol, 123 (2004) 1169-1175.

[26] J. Karar, A. Maity, PI3K/AKT/mTOR Pathway in Angiogenesis, Front Mol Neurosci, 4 (2011) 51.

[27] F. Giacco, M. Brownlee, Oxidative stress and diabetic complications, Circ Res, 107 (2010) 1058-1070.

[28] S. Singh, C. Brocker, V. Koppaka, Y. Chen, B.C. Jackson, A. Matsumoto, D.C. Thompson, V. Vasiliou, Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress, Free Radic Biol Med, 56 (2013) 89-101.

[29] A. De Becker, I.V. Riet, Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy?, World J Stem Cells, 8 (2016) 73-87.

[30] J.Y. Oh, G.E. Choi, H.J. Lee, Y.H. Jung, S.H. Ko, C.W. Chae, J.S. Kim, S.Y. Kim, J.R. Lim, C.K. Lee, H.J. Han, High Glucose-Induced Reactive Oxygen Species Stimulates Human Mesenchymal Stem Cell Migration Through Snail and EZH2-Dependent E-Cadherin Repression, Cell Physiol Biochem, 46 (2018) 1749-1767.

[31] F. Troncoso, J. Acurio, K. Herlitz, C. Aguayo, P. Bertoglia, E. Guzman-Gutierrez, M. Loyola, M. Gonzalez, M. Rezgaoui, G. Desoye, C. Escudero, Gestational diabetes mellitus is associated with increased pro-migratory activation of vascular endothelial growth factor receptor 2 and reduced expression of vascular endothelial growth factor receptor 1, PLoS One, 12 (2017) e0182509.

[32] J. Gui, A. Rohrbach, K. Borns, P. Hillemanns, L. Feng, C.A. Hubel, F. von Versen-Hoynck, Vitamin D rescues dysfunction of fetal endothelial colony forming cells from individuals with gestational diabetes, Placenta, 36 (2015) 410-418.

[33] J.N. Brantley, T.D. Verla, Use of Placental Membranes for the Treatment of Chronic Diabetic Foot Ulcers, Adv Wound Care (New Rochelle), 4 (2015) 545-559.

[34] M. Stern, The grafting of preserved amniotic membrane to burned and ulcerated surfaces, substituing skin grafts: a preliminary report, Journal of the American Medical Association, 60 (1913) 973-974.

[35] F. Nichols, A. Overly, Novel Approach for Enterocutaneous Fistula Treatment with the Use of Viable Cryopreserved Placental Membrane, Case Rep Surg, 2016 (2016) 8797691.

[36] Y. Duan-Arnold, A. Gyurdieva, A. Johnson, T.E. Uveges, D.A. Jacobstein, A. Danilkovitch, Retention of Endogenous Viable Cells Enhances the Anti-Inflammatory Activity of Cryopreserved Amnion, Adv Wound Care (New Rochelle), 4 (2015) 523-533.

[37] F. Troncoso, J. Acurio, K. Herlitz, C. Aguayo, P. Bertoglia, E. Guzman-Gutierrez, M. Loyola, M. Gonzalez, M. Rezgaoui, G. Desoye, C. Escudero, Gestational diabetes mellitus is associated with increased pro-migratory activation of vascular endothelial growth factor receptor 2 and reduced expression of vascular endothelial growth factor receptor 1, Plos One, 12 (2017).

[38] D. Yavuz, D. Balsak, C. Ekinci, A.E. Tahaoglu, C. Togrul, N. Goruk, A. Aktas, E. Karaman, Expression of VEGF and CD68 in the Placenta of Gestational Diabetic Mothers (Immunohistochemistry and Ultrastructural Study), Int J Morphol, 33 (2015) 522-526.

[39] L. Pietro, S. Daher, M.V. Rudge, I.M. Calderon, D.C. Damasceno, Y.K. Sinzato, C. Bandeira, E. Bevilacqua, Vascular endothelial growth factor (VEGF) and VEGF-receptor expression in placenta of hyperglycemic pregnant women, Placenta, 31 (2010) 770-780.

[40] M. Buemi, A. Allegra, R. D'Anna, G. Coppolino, E. Crasci, D. Giordano, S. Loddo, M. Cucinotta, C. Musolino, D. Teti, Concentration of circulating endothelial progenitor cells (EPC) in normal pregnancy and in pregnant women with diabetes and hypertension, Am J Obstet Gynecol, 196 (2007) 68 e61-66.

[41] G. Desoye, S. Hauguel-de Mouzon, The human placenta in gestational diabetes mellitus. The insulin and cytokine network, Diabetes Care, 30 Suppl 2 (2007) S120-126.

[42] J.S. Moreb, Aldehyde dehydrogenase as a marker for stem cells, Curr Stem Cell Res Ther, 3 (2008) 237-246.

[43] R.W. Storms, A.P. Trujillo, J.B. Springer, L. Shah, O.M. Colvin, S.M. Ludeman, C. Smith, Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity, Proc Natl Acad Sci U S A, 96 (1999) 9118-9123.

[44] S.E. Sherman, M. Kuljanin, T.T. Cooper, D.M. Putman, G.A. Lajoie, D.A. Hess, High Aldehyde Dehydrogenase Activity Identifies a Subset of Human Mesenchymal Stromal Cells with Vascular Regenerative Potential, Stem Cells, 35 (2017) 1542-1553.

[45] M. Lappas, U. Hiden, G. Desoye, J. Froehlich, S. Hauguel-de Mouzon, A. Jawerbaum, The role of oxidative stress in the pathophysiology of gestational diabetes mellitus, Antioxid Redox Signal, 15 (2011) 3061-3100.

[46] H. Li, Q. Yin, N. Li, Z. Ouyang, M. Zhong, Plasma Markers of Oxidative Stress in Patients with Gestational Diabetes Mellitus in the Second and Third Trimester, Obstet Gynecol Int, 2016 (2016) 3865454.

[47] G.D. Kusuma, M.H. Abumaree, A.V. Perkins, S.P. Brennecke, B. Kalionis, Reduced aldehyde dehydrogenase expression in preeclamptic decidual mesenchymal stem/stromal cells is restored by aldehyde dehydrogenase agonists, Sci Rep, 7 (2017) 42397.

[48] S. Bo, A. Lezo, G. Menato, M.L. Gallo, C. Bardelli, A. Signorile, C. Berutti, M. Massobrio, G.F. Pagano, Gestational hyperglycemia, zinc, selenium, and antioxidant vitamins, Nutrition, 21 (2005) 186-191.

[49] M. Jamilian, S. Hashemi Dizaji, F. Bahmani, M. Taghizadeh, M.R. Memarzadeh, M. Karamali, M. Akbari, Z. Asemi, A Randomized Controlled Clinical Trial Investigating the Effects of Omega-3 Fatty Acids and Vitamin E Co-Supplementation on Biomarkers of Oxidative Stress, Inflammation and Pregnancy Outcomes in Gestational Diabetes, Can J Diabetes, 41 (2017) 143-149.

[50] P. Fiorina, M. Jurewicz, A. Augello, A. Vergani, S. Dada, S. La Rosa, M. Selig, J. Godwin, K. Law, C. Placidi, R.N. Smith, C. Capella, S. Rodig, C.N. Adra, M. Atkinson, M.H. Sayegh, R. Abdi, Immunomodulatory Function of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Type 1 Diabetes, J Immunol, 183 (2009) 993-1004.

[51] K.I. Ko, L.S. Coimbra, C. Tian, J. Alblowi, R.A. Kayal, T.A. Einhorn, L.C. Gerstenfeld, R.J. Pignolo, D.T. Graves, Diabetes reduces mesenchymal stem cells in fracture healing through a TNF alpha-mediated mechanism, Diabetologia, 58 (2015) 633-642.

[52] C.L. Wu, B.O. Diekman, D. Jain, F. Guilak, Diet-induced obesity alters the differentiation potential of stem cells isolated from bone marrow, adipose tissue and infrapatellar fat pad: the effects of free fatty acids, Int J Obesity, 37 (2013) 1079-1087.

**Figure legends**

**Figure 1.**

Identification of DEGs and enriched biological functions in GDM-CMSCs. **a** Venn diagram indicates the numbers of genes up- or down- regulated >1.5-fold in GDM-CMSCs vs. Healthy-CMSCs. The overlapping areas of the 3 circles are co-regulated genes and defined as differentially expressed genes (DEGs). **b** Biological functions in “Molecular and Cellular Functions” category was generated and ranked by IPA analysis. Bars indicate over-represented functions in GDM-CMSCs compared to Healthy-CMSCs. Individual GDM-MSC samples are represented via specific indicated colours. **c** Activation state of enriched downstream cellular processes in “Molecular and Cellular Functions” using IPA activation z-score identification of increased (positive z-score) or decreased activity (negative z-score) in GDM-CMSCs compared to Healthy-CMSCs. **d** Heat maps of DEGs involved in cell survival and growth, cellular movement and assembly, skin formation and epithelial development. Expression levels are represented by log2 fold change (expression value in each sample vs. mean expression value in Healthy-CMSCs). Expression levels range from high (red) to low (green). **e** Biological functions in “Physiological System Development and Function” category in GDM-CMSCs identified by IPA. **f** Cellular processes associated with “Cardiovascular System Development and Function” in GDM-CMSCs. Activation state was calculated by IPA activation z-score. **g** Heat maps summarized DEGs involved in cardiogenesis and vasculogenesis.

**Figure 2.**

Validation of gene expression and altered biological functions in GDM-CMSCs through real-time PCR and in vitro migration assays **a** Upregulation in genes associated with cell migration/cellular assembly (*CD24, FLNB, AQP1*) and wound healing (*EDN1, HBEGF*) in GDM-CMSCs validated by real-time PCR with 10 Healthy- and 11 GDM- CMSCs samples. Gene expression levels were normalised to *GAPDH* and presented as fold change by comparing G-CMSCs to H-CMSCs using 2^-(ΔΔCt) method. **b** Motility of cell was evaluated by Transwell migration assay. Representative images of migrated Healthy-CMSCs and GDM-CMSCs stained with crystal violet after 8 and 24 hours of migration period. Scale bar: 150 μm **c** Cell migration ability was calculated by counting migrated cells per field by image J. Data represent 6 independent experiments in triplicate. **d** The graph indicates wound closure percentages and the images below are representative images of wound healing assay. Healthy-CMSCs and GDM-CMSCs migrated into the middle wound field after 12h. Percentage of wound closure was calculated by measuring the reduced wound area after 6h and 12h by image J. Data were obtained from 6 independent experiments. Scale bar: 150 μm. **e** Significant upregulation of cardiogenic genes in GDM-CMSCs. Validation of *NKX2.5, NOG,* and *PDGFA* expression in healthy and GDM samples were examined by real-time PCR. Expression level of each gene was normalised to *GAPDH*. **f** Significant downregulation of vasculogenic genes in GDM-CMSCs. *RASIP1, CXCL12*, and *RSPO3* expressions were validated by real-time PCR. Expression level of each gene was normalised to *GAPDH*. All error bars in this figure are presented as mean ± SEM. Student’s t-test was used for statistical significance, \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001.

**Figure 3.**

Positively- and negatively- regulated pathway analysis and regulatory networks visualisation **a, b** IPA canonical pathways analysis of positively- and negatively- regulated pathways in GDM-CMSCs. The x-axis indicates the altered canonical pathways in GDM-CMSCs. The left y-axis indicates the statistical significance p value, calculated using the Fisher’s exact test. The right y-axis represents the ratio of number of dataset genes that map to all known pathway genes. **c, d** Positively-regulated canonical pathways and associated genes. Hierarchical clustering maps indicate the expression of genes involved in BMP, Wnt/β-catenin, FGF signalling and Rho family signalling. From left to right on the clustering maps are presenting as GDM6, GDM7, GDM8 sample. Each gene is normalised to a mean expression of 3 Healthy-CMSCs samples. Blue and red indicates below and above mean expression respectively with values indicating log2 fold change. **e, f** Negatively-regulated canonical pathways and associated genes. Interaction networks were generated by Cytoscape visualization based on DEGs. Hierarchical clustering map showed significant reduction in ALDH family gene expression in GDM-CMSCs and regulators of Nrf2 pathway.

**Figure 4.**

Decreased ALDH activity and increased cellular ROS level in GDM-CMSCs. **a, b, c** Expressions of *ALDH1A1, ALDH2, ALDH3B1* were validated by real-time PCR with 10 Healthy- and 11 GDM- CMSCs samples. Gene expression levels were normalised to *GAPDH* and presented as fold change by comparing G-CMSCs to H-CMSCs using 2^-(ΔΔCt) method. **d** ALDH activity colorimetric assay of ALDH enzymatic function in Healthy- and GDM-CMSCs. Results obtained from 6 independent experiments in duplicate. GDM-CMSCs showed reduced ALDH activity compared to Healthy-CMSCs. **e** Real-time PCR of Nrf2-mediated oxidative stress pathway genes; NQO1 and SOD2 were significantly reduced in GDM-CMSCs. Gene expression levels were normalised to *GAPDH.* **f** ROS production determined by DCFDA staining (green). Representative fluorescent images of ROS level are shown from 3 independent experiments at different time point and imaged by confocal microscopy. Scale bar: 100 μm **g** Time-course measurement of ROS production measured by fluorescent intensity. The initial fluorescence intensity at 0 min was set at 100%. Results obtained from 6 independent experiments in triplicate. **h, i** H-CMSCs and GDM-CMSCs ALDH function inhibited by 100 mM DEAB. ALDH enzymatic functions were examined and ROS generation evaluated by DCFDA fluorescent intensity. All error bars in this figure are presented as mean ± SEM. Student’s t-test was used for statistical significance, \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001.

**Table 1. Primer sequences**

|  |  |  |
| --- | --- | --- |
| Genes | Forward sequence | Reverse sequence |
| CD24 | CTCCTACCCACGCAGATTTATTC | AGAGTGAGACCACGAAGAGAC |
| AQP1 | CTGCATGGTCAAGCCTCTTA | TCAAGGGAGTGGGTGAATTG |
| FLNB | TGATCTATGTGCGCTTCGGT | GACATGCATTTACCGGTGCC |
| CELSR1 | TACTTCTGCGGTGCTGGTTT | GTCCGTAAACCGTCCCTTCC |
| EDN1 | CCATGAGAAACAGCGTCAAATC | CGAAGGTCTGTCACCAATGT |
| HBEGF | AATCTGGCTTAGTGCCACCC | GCACTCTGACCACGGAAGAT |
| TGFB2 | ATGCGGCCTATTGCTTTAGA | ACCCTTTGGGTTCGTGTATC |
| CTCF | GCCTGTTCCAAGACCTGTG | GGCGGCTCTGCTTCTCTA |
| NKX2.5 | CAACATGACCCTGAGTCCCC | TAATCGCCGCCACAAACTCT |
| NOG | CATGCCGAGCGAGATCAAA | CAGCCACATCTGTAACTTCCTC |
| PDGFA | GGAACGCACCGAGGAAGA | GCCAGGAGGAGGAGAAACAG |
| NPPB | TGGAAACGTCCGGGTTACAG | GACTTCCAGACACCTGTGGG |
| MET | TGGTGCAGAGGAGCAATGG | CATTCTGGATGGGTGTTTCCG |
| CXCL12 | ATGAACGCCAAGGTCG | GGGCTACAATCTGAAGGG |
| RASIP1 | CGTCTCCTTGAGAACCAATACC | CATTCCACGCGGGATAAGAA |
| RSPO3 | CACCTTTATCTGAGCCAATGGA | ATGCAGGGGGATCTGACATA |
| HMOX1 | TCTTGGCTGGCTTCCTTACC | GGATGTGCTTTTCGTTGGGG |
| ALDH1A1  | TCAAACCAGCAGAGCAAACT | TAGGCCCATAACCAGGAACA |
| ALDH2 | CTGCTGACCGTGGTTACTT | CTCCCAACAACCTCCTCTATG |
| ALDH3B1 | GCTGAAGCCATCGGAGATTAG | GCTCCCTGTGAAGAAGATGTAG |
| NQO1 | GGGATGAGACACCACTGTATTT | AGTGATGGCCCACAGAAAG |
| SOD2 | GGACAAACCTCAGCCCTAAC | GCCGTCAGCTTCTCCTTAAA |
| GAPDH | ACTTCAACAGCACACCCACT | GCCAAATTCGTTGTCATACCAG |

**Table 2. Top 10 up-regulated and down-regulated genes in GDM-CMSCs vs. Healthy-CMSCs**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Top 10down-regulated genes | Average log2 ratio |   | Top 10up-regulated genes | Average log2 ratio |
| PRKCB | -5.566 | RPS4Y1 | 9.873 |
| GJA8 | -4.166 | COL17A1 | 9.344 |
| CXCL12 | -3.436 | DDX3Y | 8.528 |
| FAM20A | -3.379 | CDH1 | 8.376 |
| ALDH1A1 | -3.315 | KRT5 | 8.308 |
| PRRX2 | -3.227 | SCEL | 8.207 |
| ATP8B4 | -3.040 | SPRR3 | 7.823 |
| RSPO3 | -2.927 | PLD5 | 7.293 |
| CXCL3 | -2.925 | HAPLN1 | 7.102 |
| CXCL1 | -2.914 | L1TD1 | 6.996 |